Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	11/30/1955
Sex:	Male
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Alzheimer's Disease Markers, CSF

ARUP test code 3017653

Phospho-Tau(181)/Abeta42 Ratio, CSF	<0.011	(Ref Interval: <=0.023)

A negative result, defined as pTau181/Abeta42 ratio value below cutoff, is consistent with a negative amyloid positron emission tomography (PET) scan result. A negative result reduces the likelihood that a patient's cognitive impairment is due to AD.

The measured Abeta42 concentration is above the assay measuring limit of 2500 pg/mL. The normal CSF concentration of Abeta42 present in this individual is not consistent with the presence of pathological changes associated with Alzheimer's disease.

The pTau181 concentration was 27.4 pg/mL (Central 95%: 8.5 - 40.9 pg/mL) and the Abeta42 concentration was >2500 pg/mL (Central 95%: 514 - >2500 pg/mL). These assays are not intended to be used as stand-alone tests. The ratio of pTau181/Abeta42 should be used for clinical interpretation. Provided ranges for the individual components are based on the central 95% of cognitively normal healthy controls and not intended to be used for interpretation for specific clinical conditions.

Total-Tau/Abeta42 Ratio, CSF	<0.125	(Ref Interval: <=0.280)

A negative result, defined as tTau/Abeta42 ratio value below cutoff, is consistent with a negative amyloid positron emission tomography (PET) scan result. A negative result reduces the likelihood that a patient's cognitive impairment is due to AD.

The measured Abeta42 concentration is above the assay measuring limit of 2500 pg/mL. The normal CSF concentration of Abeta42 present in this individual is not consistent with the presence of pathological changes associated with Alzheimer's disease.

The tTau concentration was 312 pg/mL (Central 95%: 103 - 375 pg/mL) and the Abeta42 concentration was >2500 pg/mL (Central 95%: 514 - >2500 pg/mL). These assays are not intended to be used as stand-alone tests. The ratio of tTau/Abeta42 should be used for clinical interpretation. Provided ranges for the individual components are based on the central 95% of cognitively normal healthy controls and not intended to be used for interpretation for specific clinical conditions.

Interpretive information: Total-Tau/Abeta42 Ratio, CSF

CSF panel is intended for use in adult patients aged 55 years and older being evaluated for Alzheimers disease (AD) and other causes of cognitive impairment. The pTau181/Abeta42 and

H=High, L=Low, *=Abnormal, C=Critical

tTau/Abeta42 ratios provide better concordance with amyloid positron emission tomography (PET) imaging when compared to Abeta42, pTau181, and tTau individually.

Limitations: Failure to adhere to the sample collection instructions provided in the Lab Test Catalog may result in falsely reduced Abeta42 concentrations and therefore false elevations in the reported ratios. The ratios reported have not been established for predicting development of dementia or other neurologic conditions or for monitoring responses to therapies. Results of this test must always be interpreted in the context other clinical diagnostic evaluations and should not be used alone to establish a diagnosis of AD or other cognitive disorder.

Methodology: Roche Diagnostics Inc. electrochemiluminescence assay was used. Results obtained with different assay methods or kits may be different and cannot be used interchangeably.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Phospho-Tau(181)/Abeta42 Ratio, CSF	25-226-111932	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Total-Tau/Abeta42 Ratio, CSF	25-226-111932	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART